DEVELOPMENT OF HYDROGEL FORMULATIONS OF SELECTED ANTIFUNGAL DRUGS USING CYCLODEXTRIN BASED NANOSPONGES AS A CARRIER

MD APSAR PASHA; SEEMA TOMAR; KIRAN KUMAR Y.

doi:10.22159/ijap.2025v17i3.52303

Authors

MD APSAR PASHA Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, Uttarakhand-247661, India
SEEMA TOMAR Faculty of Pharmaceutical Sciences, Motherhood University, Roorkee, Uttarakhand-247661, India
KIRAN KUMAR Y. Department of Pharmaceutics, Gate Institute of Pharmaceutical Sciences, Ramapuram (V), Kodad, Chilkuru (M), Nalgonda (D), Chilkuru, Suryapet-508206, Telangana, India

DOI:

https://doi.org/10.22159/ijap.2025v17i3.52303

Keywords:

Posaconazole, Box-behnken design, Nanosponges, Freeze drying, Inclusion complex, Skin permeability

Abstract

Objective: This project will construct a Cyclodextrin-Based Nanosponge (CDNS) gel and test its topical skin application to improve Posaconazole's (PO) therapeutic impact, distribution, and preservation.

Methods: Using convection heating, Cyclodextrin (CDs) (β-CD, 2-HP-β-CD, and SBE-β-CD) were employed to crosslink diphenylcarbonate Nanosponge (NS). Make Posaconazole-Loaded Nanosponges (PONS) by freeze-drying. Box–Behnken Experimental Design (BBD) was used to formulate Carbopol 974 (1–3%, w/w), Propylene glycol (5–10%), and ethanol (10–20%, w/w). The relationship between procedural parameters and quality factors was examined using statistical screening. Analysis of Variance (ANOVA) was used for pilot studies. Key techniques affect contour, Response Surface Methodology (RSM), and perturbation graph quality measures.

Results: The average particle size of plain NS was 120–220 nm, while PO loaded ones were 48–51 nm with low Polydispersity Index (PDI). High Zeta Potential (ZP) suggests stable, low-agglomeration chemicals. The formulation demonstrated strong encapsulation efficiency (85.78±4.13%) with a viscosity range of 3476.34±213.12 to 3538.28±164.24 and showed 14% degradation over three months. All test formulations exhibited significantly higher PO skin penetration 12 h post-application (range: 41.64±1.72 μg/cm² to 54.12±1.89 μg/cm²) compared to the control group (5.68±0.23 μg/cm²). In vitro release tests indicated NS complexes released medicines faster than pure medications. PONS3, PONS7, and PONS12 with controlled release were chosen for topical hydrogel research due to their effective PO release regulation. NS resisted photodegradation and chemical degradation of PO for 6 mo. Model carbopol gel with NS compositions tested skin permeability, antifungal efficacy, and stability. PONS steadily permeated rat skin for 12 h.

Conclusion: The slow drug release, greater skin penetration, and superior storage stability of the gel formulation based on CDNS of PO imply that it has great potential as a topical delivery system.

References

Indiramuzib Y, Sreevidya P. Pulmonary drug delivery systems of posaconazole: development and optimization through quality by design. Int J Appl Pharm. 2024 May;16(5):51163. doi: 10.22159/ijap.2024v16i5.51163.

Herbrecht R. Posaconazole: a potent extended spectrum triazole anti‐fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004 Jun;58(6):612-24. doi: 10.1111/j.1368-5031.2004.00167.x, PMID 15311563.

Varghese FS, Meutiawati F, Teppor M, Jacobs S, DE Keyzer C, Taskopru E. Posaconazole inhibits multiple steps of the alphavirus replication cycle. Antiviral Res. 2022 Jan;197:105223. doi: 10.1016/j.antiviral.2021.105223, PMID 34856248.

Waghmare SM, Barve KB, Ruchake NK. A review on biological activity of 1, 3-diazole derivatives. Int J Curr Pharm Res. 2022 May;14(5):1-3. doi: 10.22159/ijcpr.2022v14i5.2030.

Wong TY, Loo YS, Veettil SK, Wong PS, Divya G, Ching SM. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. Sci Rep. 2020 Jan;10(1):14575. doi: 10.1038/s41598-020-71571-0, PMID 32884060.

Chen L, Krekels EH, Verweij PE, Buil JB, Knibbe CA, Bruggemann RJ. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020 Jul;80(7):671-95. doi: 10.1007/s40265-020-01306-y, PMID 32323222.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J Infect Dis. 2011 Sep;203(9):1324-32. doi: 10.1093/infdis/jir023, PMID 21357943.

LI Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379-96. doi: 10.2165/11319340-000000000-00000, PMID 20481649.

Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmacol. 2015 Mar;8(3):321-34. doi: 10.1586/17512433.2015.1034689, PMID 25916666.

Kersemaekers WM, Dogterom P, XU J, Marcantonio EE, DE Greef R, Waskin H. Effect of a high fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015 Jun;59(6):3385-9. doi: 10.1128/AAC.05000-14, PMID 25824210.

Sanaei Oskouei SS, Araman AO, Erginer YO. Preparation optimization and in vitro drug release study of microemulsions of posaconazole. J Drug Deliv Sci Technol. 2023 Jan;79:104090. doi: 10.1016/j.jddst.2022.104090.

Dekkers BG, Bakker M, Van Der Elst KC, Sturkenboom MG, Veringa A, Span LF. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016 Feb;10(2):51-61. doi: 10.1007/s12281-016-0255-4, PMID 27358662.

Sravya NJ, Vijetha KA. Formulation and evaluation of posaconazole bilayer delayed release tablets using solid dispersion technique. Sch Int J Linguist Lit. 2022 Sep;5(9):276-88. doi: 10.36348/sijll.2022.v05i09.006.

Kolipaka T, Sen S, Mane SS, Bajad GD, Dengale SJ, Ranjan OP. Development of posaconazole nanosuspension for bioavailability enhancement: formulation optimization in vitro characterization and pharmacokinetic study. J Drug Deliv Sci Technol. 2023 May;83:104434. doi: 10.1016/j.jddst.2023.104434.

Ghurghure SM, Jadhav T, Kale S, Phatak AA. Formulation and evaluation of posaconazole loaded nanostructured lipid carriers for topical drug delivery system. CTPPC. 2022 Mar;4(3):126-34. doi: 10.18231/j.ctppc.2022.022.

Gautham TV, Patel R, Gupta VR, Devi GP, Dharamsi A. Oral formulation of posaconazole in nanosuspension: development and optimization by design of experiments approach. Asian J Pharm. 2023 Feb;17(2):221.

Yenilmez E, Demirel M, Başaran E, Aykac K. Posaconazole loaded ocular inserts for antifungal activity. JPT. 2020;1(1):1-6. doi: 10.37662/jpt.2020.0.

Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E. Lipid based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009 Jun;26(6):523-80. doi: 10.1615/critrevtherdrugcarriersyst.v26.i6.10, PMID 20402623.

Santana AC, Nadvorny D, DA Rocha Passos TD, DE LA Roca Soares MF, Soares Sobrinho JL. Influence of cyclodextrin on posaconazole stability release and activity: improve the utility of the drug. J Drug Deliv Sci Technol. 2019 Oct;53:101153. doi: 10.1016/j.jddst.2019.101153.

Tang P, Wang L, MA X, XU K, Xiong X, Liao X. Characterization and in vitro evaluation of the complexes of posaconazole with β- and 2,6-di-O-methyl-β-cyclodextrin. AAPS Pharm Sci Tech. 2017;18(1):104-14. doi: 10.1208/s12249-016-0497-z, PMID 26883260.

Abbas N, Parveen K, Hussain A, Latif S, UZ Zaman S, Shah PA. Nanosponge based hydrogel preparation of fluconazole for improved topical delivery. Trop J Pharm Res. 2019 Feb;18(2):215-22. doi: 10.4314/tjpr.v18i2.1.

Sarfaraz MD, Shaikh ZM, Doddayya H. Preparation and characterization of fluconazole topical nanosponge hydrogel. Int J Pharm Pharm Sci. 2024 Apr;16(4):18-26. doi: 10.22159/ijpps.2024v16i4.50589.

Subair TK, Mohanan J. Development of nano based film forming gel for prolonged dermal delivery of luliconazole. Int J Pharm Pharm Sci. 2022 Feb;14(2):31-41. doi: 10.22159/ijpps.2022v14i2.43253.

Bhagyavathi A, Lakshmi S TK, Sahitya DM, Bhavani B. Nanosponges a revolutionary targeted drug delivery nanocarrier: a review. Asian J Pharm Clin Res. 2023 Apr;16(4):3-9.

Singireddy A, Pedireddi SR, Subramanian S. Optimization of reaction parameters for synthesis of cyclodextrin nanosponges in controlled nanoscopic size dimensions. J Polym Res. 2019;26(93):1-2.

Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating dexamethasone for ocular delivery: formulation design physicochemical characterization safety and corneal permeability assessment. J Biomed Nanotechnol. 2013 Jun;9(6):998-1007. doi: 10.1166/jbn.2013.1594, PMID 23858964.

Singireddy A, Subramanian S. Cyclodextrin nanosponges to enhance the dissolution profile of quercetin by inclusion complex formation. Part Sci Technol. 2016 Mar;34(3):341-6. doi: 10.1080/02726351.2015.1081658.

Chaudhary H, Rohilla A, Rathee P, Kumar V. Optimization and formulation design of carbopol loaded piroxicam gel using novel penetration enhancers. Int J Biol Macromol. 2013 Apr;55:246-53. doi: 10.1016/j.ijbiomac.2013.01.015, PMID 23376559.

Ibrahim MM, Sammour OA, Hammad MA, Megrab NA. In vitro evaluation of proniosomes as a drug carrier for flurbiprofen. AAPS Pharm Sci Tech. 2008 Mar;9(3):782-90. doi: 10.1208/s12249-008-9114-0, PMID 18587650.

Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly AE. Formulation of tretinoin loaded topical proniosomes for treatment of acne: in vitro characterization skin irritation test and comparative clinical study. Drug Deliv. 2015 Jun;22(6):731-9. doi: 10.3109/10717544.2014.896428, PMID 24670094.

Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. A novel vesicular carrier transethosome for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 2012 Apr 1;92:299-304. doi: 10.1016/j.colsurfb.2011.12.004, PMID 22205066.

Vicentini FT, Fonseca YM, Pitol DL, Iyomasa MM, Bentley MV, Fonseca MJ. Evaluation of protective effect of a water in oil microemulsion incorporating quercetin against UVB-induced damage in hairless mice skin. J Pharm Pharm Sci. 2010 Feb;13(2):274-85. doi: 10.18433/j3830g, PMID 20816012.

Nazzaro F, Fratianni F, Coppola R, DE Feo VD. Essential oils and antifungal activity. Pharmaceuticals (Basel). 2017 Apr;10(4):86. doi: 10.3390/ph10040086, PMID 29099084.

Milanowski B, Wosicka Frackowiak H, Glowka E, Sosnowska M, Wozny S, Stachowiak F. Optimization and evaluation of the in vitro permeation parameters of topical products with non-steroidal anti-inflammatory drugs through Strat-M® membrane. Pharmaceutics. 2021 Aug;13(8):1305. doi: 10.3390/pharmaceutics13081305, PMID 34452264.

Hummer J, Birngruber T, Sinner F, Page L, Toner F, Roper CS. Optimization of topical formulations using a combination of in vitro methods to quantify the transdermal passive diffusion of drugs. Int J Pharm. 2022;620:121737. doi: 10.1016/j.ijpharm.2022.121737, PMID 35413396.